Literature DB >> 17479394

Interaction index and different methods for determining drug interaction in combination therapy.

J J Lee1, M Kong, G D Ayers, R Lotan.   

Abstract

Studying and understanding the joint effect of combined treatments is important in pharmacology and in the development of combination therapies. The Loewe additivity model is one of the best general reference models for evaluating drug interactions. Based on this model, synergy occurs when the interaction index is less than one, while antagonism occurs when interaction index is greater than one. We expanded the meaning of the interaction index, and propose a procedure to calculate the interaction index and its associated confidence interval under the assumption that the dose-effect curve for a single agent follows Chou and Talalay's median effect equation. In addition, we review four response surface models based on the Loewe additivity model using a single parameter to determine drug interactions. We describe each of these models in the context of Loewe additivity model and discuss their relative advantages and disadvantages. We also provide S-PLUS/R code for each approach to facilitate the implementation of these commonly used methods.

Mesh:

Substances:

Year:  2007        PMID: 17479394     DOI: 10.1080/10543400701199593

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  55 in total

1.  A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

Authors:  Keith C Bible; Prema P Peethambaram; Ann L Oberg; William Maples; David L Groteluschen; Matthew Boente; Jill K Burton; Leigh C Gomez Dahl; Jennifer D Tibodeau; Crescent R Isham; Jacie L Maguire; Viji Shridhar; Andrea K Kukla; Kalli J Voll; Mathew J Mauer; Alexander D Colevas; John Wright; L Austin Doyle; Charles Erlichman
Journal:  Gynecol Oncol       Date:  2012-06-01       Impact factor: 5.482

2.  The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.

Authors:  Ting-Chao Chou
Journal:  Am J Cancer Res       Date:  2011-08-05       Impact factor: 6.166

3.  A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies.

Authors:  Violeta G Hennessey; Gary L Rosner; Robert C Bast; Min-Yu Chen
Journal:  Biometrics       Date:  2010-12       Impact factor: 2.571

4.  A semiparametric response surface model for assessing drug interaction.

Authors:  Maiying Kong; J Jack Lee
Journal:  Biometrics       Date:  2007-09-26       Impact factor: 2.571

5.  Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction.

Authors:  J Jack Lee; Maiying Kong
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

6.  Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates.

Authors:  Constance Lay-Lay Saw; Melvilí Cintrón; Tien-Yuan Wu; Yue Guo; Ying Huang; Woo-Sik Jeong; Ah-Ng Tony Kong
Journal:  Biopharm Drug Dispos       Date:  2011-06-08       Impact factor: 1.627

7.  Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.

Authors:  Wei Zhang; Michael Peyton; Yang Xie; Junichi Soh; John D Minna; Adi F Gazdar; Eugene P Frenkel
Journal:  J Thorac Oncol       Date:  2009-02       Impact factor: 15.609

8.  Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

Authors:  Shyril O'Steen; Damian J Green; Ajay K Gopal; Johnnie J Orozco; Aimee L Kenoyer; Yukang Lin; D Scott Wilbur; Donald K Hamlin; Darrell R Fisher; Mark D Hylarides; Theodore A Gooley; Amelia Waltman; Brian G Till; Oliver W Press
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

9.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

10.  Drug interaction: focusing on response surface models.

Authors:  Soo-Il Lee
Journal:  Korean J Anesthesiol       Date:  2010-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.